The study investigated a new non-antibiotic triple therapy for the treatment of Helicobacter pylori infection in patients with functional dyspepsia unresponsive to conventional antibiotic therapy. The treatment consisted of Weis granules, berberine hydrochloride and Bio-Three probiotic formulation containing three types of bacteria. Forty-eight patients who had previously failed at least two eradication therapies were included in a two-center retrospective analysis. Successful eradication of H. pylori was achieved in 72.9% of patients, with symptom relief observed in 77.08% of cases, of which 43.75% achieved effective improvement and 33.33% marked improvement. Adverse effects were mild and occurred in only 8.3% of patients, all of which resolved spontaneously. The treatment compliance rate was high – 91.67%. The results suggest that this non-antibiotic therapy could be an alternative for patients resistant to standard antibiotic treatment, but the authors emphasize the need for further research to verify its long-term efficacy and mechanisms of action.